R35CA263813

Stalled Replication Fork Repair in Cancer Predisposition and Cancer Therapy - Project Summary

Error-free DNA repair initiated at the sites of replication fork stalling is critical for the prevention of genomic instability in cycling cells. Defects in stalled fork repair have been directly implicated in cancer predisposition and other human diseases. The clinical burden associated with failed stalled fork repair may include hereditary breast and ovarian cancer (HBOC) predisposition, in light of the involvement of BRCA1 and BRCA2 in repair of stalled replication forks, and Fanconi anemia (FA) - a rare, autosomal recessive (or X-linked) disease caused by inactivation of any one of several FA genes.

Our work previously established roles for BRCA1 and BRCA2 in regulating homologous recombination (HR) at both double strand breaks (DSBs) and in stalled fork repair. We developed innovative tools for quantifying HR and other repair outcomes at stalled mammalian replication forks and, more recently, at broken replication forks. A major goal of this proposal is to define the fundamental mechanisms of repair of stalled forks. We have developed an array of cutting-edge tools to support this study, including unique, sophisticated HR reporters that can distinguish between error-free "short tract" HR and error-prone "long tract" HR - a replicative response analogous to break-induced replication in yeast.

One unusual aberrant replicative response that we observe at stalled forks specifically in BRCA1 mutant cells is the formation of <10 KB non-homologous tandem duplications (TDS). In a paradigm-shifting discovery, we found that these highly specific forms of structural variation are also abundant in the human BRCA1-linked breast and ovarian cancer genome. A major goal of this proposal is to define the genetic regulation and full mechanism of TD formation at stalled forks in BRCA1 mutant cells. Success in this project will reveal, in unprecedented detail, the mechanisms that regulate mammalian stalled (or broken) fork repair and their relationship to cancer predisposition.

In support of this, we will develop new techniques for analyzing DNA structural intermediates, chromatin responses to fork stalling, and protein composition of the stalled mammalian replication fork. These analytical studies may also identify new molecular targets for therapy of breast and ovarian cancer. Indeed, our recent work on the mechanisms underlying formation of BRCA1-linked TDS led us to discover a synthetic lethal interaction between BRCA1 and FANCM loss-of-function mutations. FANCM is a motor protein and, hence, an ATPase. We find that ablation of FANCM ATPase activity alone (leaving the rest of the protein intact and stable within the cell) is sufficient to confer lethality on BRCA1 mutant cells. Thus, FANCM may be a "druggable" target for therapy in BRCA1-linked cancer. In work proposed herein, we will define the therapeutic potential of this discovery.

During the funding period, we expect to make important discoveries in this field and to open the door to new therapies in HBOC and perhaps other forms of cancer.

Beth Israel Deaconess Medical Center

NOT APPLICABLE

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

Boston, Massachusetts 022155400 United States

Single Zip Code

NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed) (PAR-21-333)

Amendment Since initial award the total obligations have increased 397% from $1,022,022 to $5,078,247.